Hemophilia A Market

Apr 27, 2020

10 likes | 34 Vues

The market size of Hemophilia A was found to be USD 6,266 Million in 2017. The total diagnosed and treated a prevalent population of Hemophilia A was found to be 38,212 in 2017 (in the 7 MM). The popularity of Gene Therapy, Development of Novel Treatments with an extended half-life, and Increased Focus on Prophylactic Treatment are some of the leading factors expected to drive the Hemophilia A market in the coming years. The key players in the Hemophilia A market include Biomarin Pharmaceutical, Novo Nordisk, Sanofi, Pfizer, Catalyst Biosciences, OPKO Biologics, Spark Therapeutics, Sangamo therapeutics and others. For more details visit: https://www.delveinsight.com/report-store/hemophilia-a2030-market #hemophilia #medicine #treatment #prophylaxis #hemophilia #patients #geneticdisorder #geneticdisease

DelveInsight

Télécharger la présentation

Hemophilia A Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D